Leadership

Dr. Ira Kirschenbaum

In America, joint replacement surgeries are rather common procedures that one can elect to have. Today, patients are electing to get surgical procedures at much younger ages. According to a recent study, the average age of knee replacement surgeries is now 65 years . This study was highlighted at a recent meeting with surgeons from around the world. Dr. Ira Kirschenbaum, Director of Orthopaedics at Bronxcare Health System performs surgeries on patients and often works with other orthopedic surgeons who specialize in joint replacement.

Dr.Ira Kirschenbaum studied at Brown University and earned a medical degree from the Albert Einstein College of Medicine. Dr. Kirschenbaum resceived highly specialized training for joint replacement surgeries. Dr. Ira Kirschenbaum often goes on the lecture circuit expounding on the benefits of joint replacement surgery. He is a prolific writer as well, producing well-researched articles about information technology, as well as process re-engineering in the medical field.

According to Dr.Ira Kirschenbaum, the decrease in average age for joint replacement surgery is an indicator of a rapid increase in health problems.

Obesity has been found to be an instrumental factor in lowering the age of joint replacement surgery.

When Dr. Ira Kirschenbaum is considering a patient as a candidate for knee replacement surgery or hip replacement surgery, he must evaluate whether or not the procedure will bring a significant improvement to the patient’s quality of life. Sometimes, Dr. Ira Kirschenbaum may recommend other measures to help his patients such as exercise, a change in diet, and reducing stress on hips and joints.

Dr. Ira Kirschenbaum will continue to be a major voice for making positive changes to maintain the quality of a patient’s life for years to come.

Read Dr. Ira’s reviews here https://www.vitals.com/doctors/Dr_Ira_Kirschenbaum.html

The Ventures of Nitin Khanna

Nitin Khanna, an Indian born entrepreneur and investor operating out of the United States, is the CEO of Mergertech, a firm that works with and helps other entrepreneurs and people in business fields to sell and expand. He started his first software company, Saber, in 1999 with his brother, and used it for mainly government/citizen interaction. Saber garnered considerable success, growing to about 1,500 employees and gathering $300 million in revenue, which led to a buildup of credibility for Khanna. After selling Saber, Nitin Khanna began to work on Mergertech, which he founded in 2009. He used his experience and success with Saber to focus more on helping others in his field achieve similar goals to his. Khanna’s technique is to locate international buyers that are interested in smaller U.S. based startups, and then have them buy the latter for a larger sum of money than a large U.S. buyer would.

Mergertech grew significantly over the years, and Khanna has said that his success can be attributed to him surrounding himself with talented and eager people that he makes sure to communicate effectively with. He’s also very focused on setting schedules and priorities to ensure that everything moves forward quickly and efficiently. While still playing an active role in Mergertech as its CEO, Khanna began to invest in the cannabis industry upon its legalization in 2015, and was the CEO of Cura Cannabis until 2017. Khanna is still also quite active regarding new companies; he’s recently invests $5 million and Indian start-up, Isis Inc. Even throughout his successes and accumulation of wealth, Khanna insists that his motivation is to provide support and mentorship for those that were once starting out like him – this, he says, fosters a lively and ever growing atmosphere that is crucial to the field of entrepreneurship.

Read the history of Mergertech here http://affiliatedork.com/nitin-khanna-mergertech-focus

Jason Hope cooperating with SENS Research Foundation

Jason Hope is supporting anti-aging research that is meant to come up with a drug that will solve the issues surrounding the aging process in humans. Today, the aging process is seen as a natural process that cannot be resolved. It has existed as long as human history exists and not a single generation that has ever managed to overcome it. There have been attempts in the past, but none has succeeded. The anti-aging research is now ongoing in the 21st century, but this time, the chances of getting good outcome are almost becoming a reality.

SENS Research Foundation is leading anti-aging research. For the past decade, this organization has invested in activities that will lead to the creation of an anti-aging drug that will be successful for the first time. This organization has learned from the mistakes of other organizations, and they are ready to use the right methods of creating a drug that will work and solve the issue of old age diseases. In old age, many people tend to develop conditions that end up affecting their ability to live a normal life. Some common old age diseases include cancer, Parkinson’s disease, and Alzheimer’s disease.

SENS Research Foundation is now one of the leading organizations in the world that has shown the potential of inventing the first anti-aging drug. Under the leadership of Aubrey de Grey and the support of philanthropists such as Jason Hope, SENS is expected to accomplish its mission very soon. Jason Hope has been a great supporter of the anti-aging research for the past decade because he believes in the potential it is likely to bring in the world.

To show the commitment that he has in this research, Jason Hope has donated over half a million dollars to SENS Research Foundation. He has pledged to keep supporting SENS until such a time when a solution will be developed. Jason Hope is known to many as a person who has an exceptional love for technology that changes the value of human life for the better. If the aging process can be defeated, it will mean that humans will now be living for a long time with their bodies still in great shape.

About Jason Hope: medium.com/@jasonhope

How Carsten Thiel Found Early Success Marketing A Weight Loss Product

Carsten Thiel is a biotechnology executive who has worked around the world. He was the chief executive officer of Abeona Therapeutics, Inc. which creates cell and gene therapies. The focus is on helping people who have life-threatening rare genetic diseases.
He has been in the biotechnology business since 1994 when he joined Hoffman-La Roche. Carsten Thiel is originally from Germany and went to college in the United Kingdom. His career has taken him to Slovenia, Switzerland, Austria, and the United States. He currently lives in the New York City area.

Over the past 25 years, he has brought several high-profile medical products to market. Among these are Prolia, Neulasta, and Vectibix. He has been highly involved in marketing products that have improved the lives of people around the world. He says that he approaches marketing with medical ethics being the first and foremost concern. He wants to help doctors develop more cohesive patient care plans and do his part to support the provider-patient relationship.

Carsten Thiel’s early career success led to him being put in charge of the marketing campaign for a new weight loss product, Xenical. He already had experience marketing vitamins and supplements so he was well-suited to the task of getting people to know about Xenical. He started out by crafting credible and realistic communications that were sent out to health care providers. As Xenical became more established Carsten Thiel advertised to the general mass. This lead to a steady incline of people using Xenical to drop excess pounds.

He says both of his parents were medical doctors. He thought he would pursue the same path but instead chose to be in the medical field in a different way that would take advantage of his interests and abilities. He developed a keen interest in how DNA works and decided that his career path would be exploring this subject.

Carsten Thiel’s: Facebook Page.